Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.42 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.42 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.40 |
| ▸ | TK2 | O00142 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582060 | 0.86 | TK2 (0.42) | TK1TK2 | |
| SCHEMBL24512779 | 0.86 | TK2 (0.42) | TK1TK2 | |
| SCHEMBL2769235 | 0.86 | TK2 (0.42) | TK1TK2 | |
| SCHEMBL5557408 | 0.86 | TK2 (0.42) | TK1TK2 | |
| SCHEMBL6830445 | 0.83 | TK1 (0.42) | TK1NT5MRNASE1TK2 | |
| SCHEMBL6830442 | 0.83 | TK1 (0.42) | TK1NT5MRNASE1TK2 | |
| SCHEMBL3841357 | 0.81 | TK2 (0.40) | TK1TK2 | |
| SCHEMBL18315872 | 0.81 | TK1 (0.41) | TK1NT5MRNASE1TK2 | |
| SCHEMBL20484896 | 0.81 | TK2 (0.42) | TK1TK2 | |
| SCHEMBL2298778 | 0.80 | TK2 (0.42) | TK1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751909-B2 | Synthesis and uses of nucleic acid compounds with conformationally restricted monomers | MARINA BIOTECH, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20150080564-A1 | SYNTHESIS AND USES OF NUCLEIC ACID COMPOUNDS WITH CONFORMATIONALLY RESTRICTED MONOMERS | MARINA BIOTECH, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-6833361-B2 | Compound for use in the treatment of viral diseases | RIBAPHARM, INC. | 2004-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080564-A1 | SYNTHESIS AND USES OF NUCLEIC ACID COMPOUNDS WITH CONFORMATIONALLY RESTRICTED MONOMERS | POLN, NSUN2, POLM | TK1 617/4885NT5M 2114/4885RNASE1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.